

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 November 2022 (24.11.2022)



(10) International Publication Number
WO 2022/245500 A1

(51) International Patent Classification:

A61K 38/20 (2006.01) C07K 16/46 (2006.01)
A61K 47/68 (2017.01) A61K 39/395 (2006.01)
C07K 14/54 (2006.01) C07K 19/00 (2006.01)
C07K 16/28 (2006.01)

(21) International Application Number:

PCT/US2022/026584

(22) International Filing Date:

27 April 2022 (27.04.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/190,669	19 May 2021 (19.05.2021)	US
63/223,684	20 July 2021 (20.07.2021)	US
PCT/US2021/056312	22 October 2021 (22.10.2021)	US
PCT/US2021/062485	08 December 2021 (08.12.2021)	US
63/297,631	07 January 2022 (07.01.2022)	US

(71) Applicant: **ASHER BIOTHERAPEUTICS, INC.**
[US/US]; 650 Gateway Boulevard, Suite 100, South San Francisco, California 94080 (US).


(72) Inventors: **YEUNG, Yik Andy**; 650 Gateway Boulevard, Suite 100, South San Francisco, California 94080 (US). **GREER, Renee L.**; 650 Gateway Boulevard, Suite 100, South San Francisco, California 94080 (US). **NGUYEN, Henry C.**; 650 Gateway Boulevard, Suite 100, South San Francisco, California 94080 (US). **LIU, David**; 650 Gateway Boulevard, Suite 100, South San Francisco, California 94080 (US). **KANG, Byong**; 650 Gateway Boulevard, Suite 100, South San Francisco, California 94080 (US). **DJURETIC, Ivana**; 650 Gateway Boulevard, Suite 100, South San Francisco, California 94080 (US).

(74) Agent: **HUANG, Wei**; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: IL-21 POLYPEPTIDES AND TARGETED CONSTRUCTS

FIG. 6



(57) Abstract: The present disclosure provides methods and compositions comprising IL-21 polypeptides, targeted cytokine construct that selectively activates target immune cells (e.g., CD8+ T cells) over other immune cell types. The cytokine of the present disclosure can further comprise mutations that alter its charge distribution to improve its half-life within the blood.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*